News | December 30, 2008

New Directors on TomoTherapy Board Hope to Revive Stocks

December 29, 2008 - Avalon Portfolio LLC, on Dec. 23, 2008, nominated four new directors to serve on the board of TomoTherapy Inc. as part of a strategy to generate greater value for the company’s shareholders as TomoTherapy's stock have continued to fall since stock price since 2007.

Having lost 85 percent of its value year-to-date, with most of the decline occurring prior to the meltdown of the financial markets this fall, the board is exploring all strategic options to maximize shareholder value.

TomoTherapy, which markets an integrated CT scanning and radiation therapy - the Hi-Art system - to hospitals and cancer centers, posted a net loss of $26 million on revenue of $118 million in the first three quarters of 2008, down from net income of $5.8 million on revenue of $154 million for the same period in 2007. Since November 9, 2007, the company's stock price has plummeted from $20.51 to $2.41, the closing price on Dec. 26, 2008. The stock opened at $24 in its May 2007 IPO.

Avalon’s nomination slate includes Jonathan McCloskey, portfolio manager at Avalon, Timothy Dooling, portfolio analyst at Avalon, H. Michael Collins, principal of Collins MacVean, LLC, and Andrew Jones, CEO and President of Argus Systems Group.

For more information:

Related Content

First Hospitals Achieve Inter-System Connectivity Across Accuray Radiation Therapy Platforms
News | Radiation Therapy | January 19, 2018
Accuray Inc. announced recently that the Heidelberg University Hospital in Heidelberg, Germany, and Oscar Lambret...
RayStation Selected for New Carbon Ion Therapy Center in Japan
News | Treatment Planning | January 18, 2018
January 18, 2018 – RayStation has been chosen as the treatment planning system for a new carbon-ion therapy facility
Raysearch Receives First Order for the Raycare Oncology Information System
News | Oncology Information Management Systems (OIMS) | January 18, 2018
January 18, 2018 – Anderson Regional Cancer Center (ARCC) in Meridian, Mississippi, has placed the first order for...
Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
News | Radiation Therapy | January 03, 2018
Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
News | Radiation Therapy | January 02, 2018
IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
Overlay Init